Insiders Trades
Lantern Pharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 May 2026.
Lantern Pharma Inc.: what insiders have been doing
Lantern Pharma Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 2 filings signed by 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €170k, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 2 senior executives. The largest single trade was a purchase of €85k by Schalop Lee Troy, published on 14 May 2026, equal to 0.31% of the market capitalisation.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 2 filings, this issuer sits below that mark. The full history, which starts in 2022, counts 2 purchases against 52 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -17.1 m USD.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 157 days ago, on 14 May 2026.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
60
Thresholds
n/a
Buy Volume
€170,425
2 ops. · all time
Sell Volume
€2M
52 ops. · all time
Who traded when
BuySaleAaron G.L. Fletcher17 sales
Leslie W. Kreis17 sales
D. Jeffrey Keyser1 buy
Lee Troy Schalop1 buy
Since the insiders bought
- -78.6%Entry US$3.14 · Close 14 Oct 2026 US$0.67
- -78.6%Entry US$3.14 · Close 14 Oct 2026 US$0.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Lantern Pharma Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$17.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.07
Analyst consensus
2 analystsStrong buy
US$10.00Target US$17.50(+745%)US$25.00
Income statement
EBITDA-US$18M
Net income-US$17.1M0.0% margin
Valuation
PER (forward)-1.0x
P/Book7.6x
Beta2.34
Balance sheet & cash
Market capUS$26.5M
Total debtUS$78.5k
Free Cash Flow-US$15.7M
Debt / Equity2%
Profitability & ownership
ROE-400.9%
ROA-74.3%
% insiders20.3%
% institutions22.6%
Last declaration on 14 May 2026
Declarations60 total
48,544 shares@ US$2.060.31% mcap100.0% of flowCommon stock, $0.001 par valueSEC:0001493152-26-023083:0
Canonical exit: 10 Aug 2026 (T+90)
48,544 shares@ US$2.060.31% mcap88.5% of flowCommon stock, $0.001 par valueSEC:0001493152-26-023082:0
Canonical exit: 10 Aug 2026 (T+90)
7,206 shares@ US$3.090.070% mcap2.3% of flowCommon StockSEC:0001104659-25-059526:0
3 shares@ US$3.400.0000% mcap0.0% of flowCommon StockSEC:0001104659-25-059106:0
7,206 shares@ US$3.090.070% mcap2.3% of flowCommon StockSEC:0001104659-25-059528:0
3 shares@ US$3.400.0000% mcap0.0% of flowCommon StockSEC:0001104659-25-059091:0
4,620 shares@ US$2.871.4% of flowCommon StockSEC:0001104659-25-054422:4
3,790 shares@ US$3.051.2% of flowCommon StockSEC:0001104659-25-054422:0
714 shares@ US$2.870.2% of flowCommon StockSEC:0001104659-25-054422:7
1,632 shares@ US$2.870.5% of flowCommon StockSEC:0001104659-25-054422:13
3,790 shares@ US$3.051.2% of flowCommon StockSEC:0001104659-25-054421:0
6,479 shares@ US$3.052.1% of flowCommon StockSEC:0001104659-25-054421:3
4,620 shares@ US$2.871.4% of flowCommon StockSEC:0001104659-25-054421:4
2,702 shares@ US$2.870.8% of flowCommon StockSEC:0001104659-25-054422:1
3,639 shares@ US$3.031.2% of flowCommon StockSEC:0001104659-25-054422:2
6,479 shares@ US$3.052.1% of flowCommon StockSEC:0001104659-25-054422:3
6,221 shares@ US$3.032.0% of flowCommon StockSEC:0001104659-25-054422:5
1,000 shares@ US$3.050.3% of flowCommon StockSEC:0001104659-25-054422:6
961 shares@ US$3.030.3% of flowCommon StockSEC:0001104659-25-054422:8
7,478 shares@ US$3.052.4% of flowCommon StockSEC:0001104659-25-054422:9
5,332 shares@ US$2.871.6% of flowCommon StockSEC:0001104659-25-054422:10
7,180 shares@ US$3.032.3% of flowCommon StockSEC:0001104659-25-054422:11
2,290 shares@ US$3.050.7% of flowCommon StockSEC:0001104659-25-054422:12
2,199 shares@ US$3.030.7% of flowCommon StockSEC:0001104659-25-054422:14
2,702 shares@ US$2.870.8% of flowCommon StockSEC:0001104659-25-054421:1
25 of 60 declarations
About Lantern Pharma Inc.
Lantern Pharma Inc. is a US-based biopharmaceutical company listed on the Nasdaq Stock Market in the United States under the ticker LTRN. Headquartered in Dallas, Texas, the company is focused on precision oncology and on using artificial intelligence to accelerate cancer drug discovery and development. Its principal executive offices are at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201. Lantern is positioned as a small-cap, development-stage biotech with a technology-driven business model rather than a traditional commercial pharma franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1763950/000164117225022896/formars.pdf))
The company’s core platform is RADR®, its proprietary AI and machine-learning engine for oncology. Lantern says RADR® leverages roughly 200 billion oncology-focused data points and more than 200 machine-learning algorithms to support target identification, biomarker analysis, patient stratification, and trial design. In practical terms, Lantern’s model combines artificial intelligence, genomics, cloud computing, and automated data analytics to narrow the probability of failure in early drug development and to shorten timelines. This makes Lantern a niche player at the intersection of biotechnology and health-tech, with differentiation based on data science and precision-medicine workflows. ([lanternpharma.com](https://www.lanternpharma.com/about))
Read moreShow less
Lantern’s pipeline remains centered on oncology and includes multiple investigational programs aimed at different cancer types and patient segments, including lung cancer, breast cancer, lymphoma, sarcoma, pediatric brain cancers, and bladder cancer. Recent company disclosures highlight LP-300, LP-284, and STAR-001 as important assets, with clinical and regulatory progress intended to create value through milestone execution rather than through current product sales. In that sense, Lantern remains a pipeline-and-platform story, with its long-term equity case tied to clinical readouts, regulatory progress, and potential partnerships. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates/default.aspx))
From a competitive standpoint, Lantern operates in a crowded oncology biotech market, but its AI-first approach gives it a distinct narrative versus conventional drug developers. The company is trying to convert proprietary data, model development, and biomarker-driven trial design into a repeatable development advantage. Its positioning is strengthened by the fact that it is not only advancing internal programs but also commercializing adjacent AI tools, including withZeta.ai and predictBBB.ai, which could broaden the opportunity set beyond single-asset drug development. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Launches-withZeta-ai--the-Worlds-First-Multi-Agentic-A-I--Co-Scientist-for-Rare-Cancer-Drug-Discovery--Development--Subscriptions-Now-Open-Debut-Events-at-Nasdaq-MarketSite-on-416-and-at-AACR-2026-from-417-to-422/default.aspx?utm_source=openai))
Recent news indicates a clear push to industrialize the platform. In 2026, Lantern launched withZeta.ai as a commercially live multi-agentic AI co-scientist for rare cancer drug discovery and clinical-trial development, expanded predictBBB.ai into a real-time quantitative model, and announced new regulatory progress for LP-284 as well as FDA IND clearance for a planned pediatric CNS cancer trial through Starlight Therapeutics. The company also reiterated in its 2025 annual report and 2026 business updates that its commercial and clinical efforts remain subject to funding, development, and adoption risk, which is typical for an early-stage precision oncology company. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Launches-withZeta-ai--the-Worlds-First-Multi-Agentic-A-I--Co-Scientist-for-Rare-Cancer-Drug-Discovery--Development--Subscriptions-Now-Open-Debut-Events-at-Nasdaq-MarketSite-on-416-and-at-AACR-2026-from-417-to-422/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
